Visualitza per matèria "Quimioteràpia combinada"
Ara mostrant els elements 21-40 d 101
-
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
(American Association for Cancer Research, 2021-11-01) -
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
(SAGE Publications, 2022) -
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
(Dove Medical Press, 2021-06-09) -
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
(Nature Portfolio, 2023-05) -
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
(Korean Society of Gynecologic Oncology & Colposcopy, 2021-11) -
Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
(Dove Medical Press, 2024-03-29) -
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
(American Medical Association, 2021-04) -
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
(Ferrata Storti Foundation, 2024-02) -
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
(American Association for Cancer Research, 2021-12)